The Journal of antimicrobial chemotherapy · 2022
Individual target pharmacokinetic/pharmacodynamic attainment rates among meropenem-treated patients admitted to the ICU with hospital-acquired pneumonia.
СтатьяПоддержка исследования: вне правительства СШАПоддержка NIH: внешняя программаНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rohani Roxane, Scheetz Marc H, Donnelly Helen K, Donayre Alvaro, Kang Mengjia, Diaz Estefani, Dedicatoria Kay, Hauser Alan R, Ozer Egon A, Nozick Sophia, Qi Chao, Pawlowski Anna E, Neely Michael N, Misharin Alexander V, Wunderink Richard G, Rhodes Nathaniel J, NU SCRIPT Study investigators
Аннотация
OBJECTIVES: Critical illness reduces β-lactam pharmacokinetic/pharmacodynamic (PK/PD) attainment. We sought to quantify PK/PD attainment in patients with hospital-acquired pneumonia.
METHODS: Meropenem plasma PK data (n = 70 patients) were modelled, PK/PD attainment rates were calculated for empirical and definitive targets, and between-patient variability was quantified [as a coefficient of variation (CV%)].
RESULTS: Attainment of 100% T>4×MIC was variable for both empirical (CV% = 92) and directed (CV% = 33%) treatment.
CONCLUSIONS: Individualization is required to achieve suggested PK/PD targets in critically ill patients.
METHODS: Meropenem plasma PK data (n = 70 patients) were modelled, PK/PD attainment rates were calculated for empirical and definitive targets, and between-patient variability was quantified [as a coefficient of variation (CV%)].
RESULTS: Attainment of 100% T>4×MIC was variable for both empirical (CV% = 92) and directed (CV% = 33%) treatment.
CONCLUSIONS: Individualization is required to achieve suggested PK/PD targets in critically ill patients.